This webinar was supported by Neuraxpharm

In this webinar, our panel of expert speakers discussed critical considerations of first antidepressant treatment failure and the importance of antidepressant metabolism. The international panel shared the nuances of dual-action and tolerability considerations of desvenlafaxine. The topics covered in the webinar where:

1. Why antidepressant metabolism matters? Comorbidities, drug-drug interactions and the liver.
2. What to do when first antidepressant fails? Dual action and tolerability considerations of desvenlafaxine.

Both topics were addressed from a clinical perspective by sharing real clinical cases and delving into the available evidence.

Chair:

Dr. Javier De Diego Adeliño, Psychiatrist, Hospital de la Santa Creu i Sant Pau and Associate Professor of Psychiatry of Universitat Autonoma de Barcelona.

Speakers: 

Prof. Dr. Mazda Adli, Professor for Psychiatry and Chair of Fliedner Klinik, Centre for Psychiatry, Psychotherapy and Psychosomatic Medicine Charité-u

Dr. Antonio Lains, Director of Neuroscience and Mental Health Clinic, Hospital Cruz Vermelha, Lisbon, Portugal

Prof. Dr. Claudia Carmassi, Associate Professor of Psychiatry, Psychiatric Clinic, University of Pisa Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

For a comprehensive understanding, access the “Desvenlafaxine Recommendations Report” published by the expert speakers of the webinar, which can be downloaded by clicking here